TRACER PHARMA ApS Financials, key figures and credit report
Gross profit 5 203.8 kDKK FY 2024 -3.9% vs 2023
EBIT 813.4 kDKK FY 2024 -62.7% vs 2023
Net debt -2 028.1 kDKK FY 2024 +39.7% vs 2023
Quick ratio 1.6 FY 2024 -4.3 vs 2023
Income statement (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 3 967.67 | 3 883.37 | 4 076.39 | 5 412.90 | 5 203.82 |
| Employee benefit expenses | -2 759.55 | -3 552.26 | -3 807.16 | -2 905.86 | -4 607.13 |
| Other operating expenses | - 257.00 | - 257.00 | |||
| Total depreciation | - 118.83 | - 121.92 | - 121.92 | -67.44 | -40.24 |
| EBIT | 1 089.30 | 209.19 | 147.30 | 2 182.60 | 813.44 |
| Other financial income | 22.92 | 108.27 | |||
| Other financial expenses | -22.31 | -23.24 | -21.58 | -19.18 | -14.29 |
| Pre-tax profit | 1 066.99 | 185.95 | 125.72 | 2 186.34 | 907.42 |
| Income taxes | - 234.74 | -40.91 | -28.77 | - 480.99 | - 219.55 |
| Net earnings | 832.25 | 145.04 | 96.95 | 1 705.34 | 687.87 |
Assets (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 351.53 | 229.61 | 107.68 | 40.24 | |
| Tangible assets total | 351.53 | 229.61 | 107.68 | 40.24 | |
| Investments total | 115.49 | 118.49 | 130.71 | 131.43 | |
| Long term receivables total | |||||
| Raw materials and consumables | 203.26 | 235.01 | 177.91 | 71.15 | |
| Inventories total | 203.26 | 235.01 | 177.91 | 71.15 | |
| Current trade debtors | 1 302.49 | 55.03 | 788.81 | ||
| Current amounts owed by group member comp. | 76.44 | 12.13 | 243.46 | ||
| Prepayments and accrued income | 224.06 | 101.23 | 37.58 | 110.88 | |
| Current other receivables | 64.48 | 102.22 | 76.34 | 77.33 | |
| Current deferred tax assets | 120.55 | 88.75 | 68.36 | ||
| Short term receivables total | 1 667.48 | 379.03 | 202.67 | 1 057.50 | 243.46 |
| Cash and bank deposits | 912.19 | 2 476.76 | 2 405.96 | 3 361.68 | 2 028.07 |
| Cash and cash equivalents | 912.19 | 2 476.76 | 2 405.96 | 3 361.68 | 2 028.07 |
| Balance sheet total (assets) | 3 249.96 | 3 438.90 | 3 024.93 | 4 662.01 | 2 271.52 |
Equity and liabilities (kDKK)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 80.00 | 80.00 | 80.00 | 80.00 | 80.00 |
| Shares repurchased | 350.00 | 1 000.00 | 1 900.00 | ||
| Retained earnings | 569.71 | 1 051.97 | 197.01 | -1 606.04 | 99.30 |
| Profit of the financial year | 832.25 | 145.04 | 96.95 | 1 705.34 | 687.87 |
| Shareholders equity total | 1 481.96 | 1 627.01 | 1 373.96 | 2 079.30 | 867.17 |
| Provisions | 33.64 | 3.04 | 257.00 | ||
| Non-current deferred tax liabilities | 460.61 | ||||
| Non-current liabilities total | 460.61 | ||||
| Advances received | 763.40 | 783.77 | 811.69 | 1 118.52 | |
| Current trade creditors | 59.92 | 69.24 | 67.43 | 90.83 | 80.00 |
| Short-term deferred tax liabilities | 196.02 | 151.19 | |||
| Other non-interest bearing current liabilities | 715.00 | 955.85 | 771.84 | 655.75 | 1 173.16 |
| Current liabilities total | 1 734.36 | 1 808.85 | 1 650.97 | 1 865.10 | 1 404.35 |
| Balance sheet total (liabilities) | 3 249.96 | 3 438.90 | 3 024.93 | 4 662.01 | 2 271.52 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated